Please ensure Javascript is enabled for purposes of website accessibility

This Is Why Humira Isn't AbbVie's Biggest Problem Right Now

By Cory Renauer - May 3, 2021 at 7:57AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two of AbbVie's most important assets could get a lot harder to sell.

Despite launching nearly two decades ago, worldwide sales of AbbVie's (ABBV -0.91%) lead drug, Humira still generates more revenue than most countries. As you can imagine, patent-protected exclusivity expected to expire in the U.S. in 2023 has been a major concern for AbbVie for a long time. In fact, eight years ago, Abbott spun out its biopharmaceutical segment into a separate company to protect the parent from Humira's impending patent cliff.

Overcoming Humira's far-off patent losses has been central to AbbVie's existence for so long that it can be hard to realize problems festering in the present. In case you hadn't noticed, sales of two drugs the company is relying on to offset eventual Humira losses are running into trouble and the worst is still to come.

Scientist looking at something important.

Image source: Getty Images.

The beginning of Imbruvica's end

In 2015, AbbVie acquired Pharmacyclics for about $21 billion to gain rights to the portion of sales for Imbruvica, a new cancer drug that Johnson & Johnson (JNJ 0.09%) already owned part of. AbbVie's share of Imbruvica sales grew last year to $5.3 billion, which worked out to 12% of the company's total revenue. 

Unfortunately for AbbVie, Imbruvica sales will probably get cut to shreds long before Humira begins losing ground to U.S. biosimilar competition in 2023. That's because it's a first-generation Bruton's tyrosine kinase (BTK) inhibitor that isn't nearly as targeted as next-generation BTK inhibitors from AstraZeneca (AZN 1.50%) and BeiGene (BGNE -6.91%)

Off-target effects make Imbruvica difficult to tolerate and it's already losing ground to new BTK-inhibitors with better safety profiles. Last November, the FDA approved Calquence from AstraZeneca to treat newly diagnosed patients with the most common form of leukemia. As a result, AbbVie reported Imbruvica sales in the first quarter that were 11% lower than during the previous three-month period.

Class effect

Unfortunately for AbbVie, competition for leukemia patients from next-generation BTK inhibitors is about to rise exponentially. Interim phase 3 trial results BeiGene announced in April suggested Beigene's new BTK inhibitor, Brukinsa will wipe the floor with Imbruvica when long-term survival data reads out. During the head-to-head Alpine study, relapsed leukemia patients randomized to receive Brukinsa were significantly more likely to respond to treatment than those given Imbruvica.   

Brukinsa earned its first FDA approval in 2019 to treat a rare lymphoma and it's going to be a while before BeiGene can apply for approval to treat first-line leukemia. In the meantime, though, oncologists who saw Brukinsa shrink tumors more often than Imbruvica will be even more likely to reach for available next-generation drugs from this class.

Another negative class effect

Off-target side effects aren't an issue limited to cancer treatments that inhibit out-of-control Bruton's tyrosine kinases. In February, the FDA alerted the public to the increased risk of heart problems and cancer found during a post-marketing safety study with Xeljanz. This is a Janus kinase inhibitor (JAK) from Pfizer (NYSE: PFE) the FDA approved to treat rheumatoid arthritis in 2012.

AbbVie's Rinvoq is a new JAK inhibitor the FDA approved to treat rheumatoid arthritis in 2019. Investors hoping Rinvoq will offset Humira losses should probably brace for disappointment. Xeljanz isn't the only JAK inhibitor out there with a troubled safety profile.

Don't panic

Right now, you can find better pharma stocks to buy than AbbVie, but you shouldn't dump the stock if you're already holding it. While a lot of Humira profits have been funneled into kinase inhibitors, AbbVie's bet on Allergan could produce decades of reliable sales.

It's been years since Botox has been the only brand of botulinum toxin approved by the FDA but the Botox brand still dominates. Botox sales reached an annualized $4 billion in the first quarter and this revenue stream isn't going anywhere but up for the foreseeable future.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$152.53 (-0.91%) $-1.40
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$178.30 (0.09%) $0.16
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.49 (1.50%) $0.98
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$108.69 (-0.56%) $0.61
BeiGene Stock Quote
BeiGene
BGNE
$181.05 (-6.91%) $-13.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.